<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923607</url>
  </required_header>
  <id_info>
    <org_study_id>TQC2731-I-01</org_study_id>
    <nct_id>NCT04923607</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial of TQC2731 Injection</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of TQC2731 Injection in Healthy Adult Subjects and Patients With Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in&#xD;
      patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic&#xD;
      characteristics and immunogenicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2021</start_date>
  <completion_date type="Anticipated">August 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(healthy subject)Number of participants with abnormal clinical symptoms</measure>
    <time_frame>appropriatly up to Day 253</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(healthy subject)Number of participants with abnormal physical examination</measure>
    <time_frame>appropriatly up to Day 253</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(healthy subject)Number of participants with abnormal vital signs</measure>
    <time_frame>appropriatly up to Day 253</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(asthma subject)Number of participants with abnormal laboratory examinations</measure>
    <time_frame>appropriatly up to Day 253</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the drug-time curve</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration following drug administration</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination half-life following drug administration</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance rate</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of anti-drug antibody (ADA)</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in forced expiratory volume (FEV1) in the first second before bronchodilator (before BD administration) from baseline</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in exhaled nitric oxide FENO (ppb) in the first second before bronchodilator (before BD administration) from baseline</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exhaled nitric oxide FENO (ppb), peripheral blood eosinophils, and total serum IgE</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized incidence of acute asthma attack (AAER) and degree</measure>
    <time_frame>up to Day 253</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Asthma Severe Persistent Controlled</condition>
  <arm_group>
    <arm_group_label>TQC2731 injection(sc.) in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of TQC2731(12mg、105mg、210mg、420mg、630mg) once.&#xD;
For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg TQC2731 .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo(sc.) in healthy subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of matching placebo(12mg、105mg、210mg、420mg、630mg) once.&#xD;
For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg matching placebo(12mg、105mg、210mg、420mg、630mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQC2731 injection(SAD,iv.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects received 210mg TQC2731 intravenously (iv.) once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo(SAD,iv.)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy subjects received 210mg matching placebo intravenously (iv.) once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQC2731 injection(sc.) in asthma subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of TQC2731(70mg、210mg、280mg) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo(sc.) in asthma subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.) injection of matching placebo(70mg、210mg、280mg) .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQC2731</intervention_name>
    <description>TQC2731 injection</description>
    <arm_group_label>TQC2731 injection(SAD,iv.)</arm_group_label>
    <arm_group_label>TQC2731 injection(sc.) in asthma subjects</arm_group_label>
    <arm_group_label>TQC2731 injection(sc.) in healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo with no active ingredients</description>
    <arm_group_label>Matching Placebo(SAD,iv.)</arm_group_label>
    <arm_group_label>Matching Placebo(sc.) in asthma subjects</arm_group_label>
    <arm_group_label>Matching Placebo(sc.) in healthy subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects:Sign the informed consent form before the trial, fully understand the&#xD;
             trial purpose, process and possible adverse reactions.&#xD;
&#xD;
          -  Healthy subjects:Aged between 18 and 60 years old, both men and women;&#xD;
&#xD;
          -  Healthy subjects:Female ≥45kg, male ≥50kg, body mass index (BMI) is 18-28 kg/m^2&#xD;
             (including the critical value), BMI=weight (kg)/height^2 (m^2);&#xD;
&#xD;
          -  Asthma subjects:Aged between 18 and 70 years old, both men and women;&#xD;
&#xD;
          -  Asthma subjects:Female ≥45kg, male ≥50kg;&#xD;
&#xD;
          -  Asthma subjects:according to the GINA guidelines (GINA 2020), subjects who received&#xD;
             middle, or high-dose ICS in asthma control drugs prescribed by the doctor at least 6&#xD;
             months prior to Visit 1;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects: Pregnant and lactating women;&#xD;
&#xD;
          -  Healthy subjects:preexisting or existing heart, endocrine, metabolism, kidney, liver,&#xD;
             gastrointestinal, skin, infection, blood, nerve, mental diseases or abnormalities, or&#xD;
             related chronic or acute diseases, the investigator assesses that it is not&#xD;
             appropriate to participate in the trial;&#xD;
&#xD;
          -  Healthy subjects:Those whose vital signs, physical examination, laboratory&#xD;
             examination, 12-lead electrocardiogram, and chest radiograph during the screening&#xD;
             period are abnormal and have clinical significance;&#xD;
&#xD;
          -  Healthy subjects:Hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody&#xD;
             (Anti-HCV), human immunodeficiency virus antibody (Anti-HIV) and Treponema pallidum&#xD;
             antibody (Anti-TP), any of the above positive subjects;&#xD;
&#xD;
          -  Healthy subjects:A history of clinically significant infections before and during&#xD;
             screening, including upper respiratory tract infection (URTI) and lower respiratory&#xD;
             tract infection (LRTI), and requires antibiotic or antiviral treatment;&#xD;
&#xD;
          -  Healthy subjects:Those who have undergone surgery within 4 weeks before screening, or&#xD;
             plan to undergo surgery during the study period;&#xD;
&#xD;
          -  Asthma subjects: Pregnant and lactating women;&#xD;
&#xD;
          -  Asthma subjects:Patients with abnormal vital signs, physical examination, 12-lead&#xD;
             electrocardiogram results and clinical significance during the screening period;&#xD;
&#xD;
          -  Asthma subjects:preexisting or existing heart, endocrine, metabolism, kidney, liver,&#xD;
             gastrointestinal, skin, infection, blood, nerve, or mental illness, etc., or related&#xD;
             chronic or acute diseases, the investigator's assessment should not participate in the&#xD;
             trial; (except for the target disease)&#xD;
&#xD;
          -  Asthma subjects:Accompanied by clinically major lung diseases other than asthma (for&#xD;
             example, active lung infection, non-asthmatic chronic obstructive pulmonary disease&#xD;
             (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis, obesity-related&#xD;
             Hypoventilation syndrome, lung cancer, α1 antitrypsin deficiency, and primary ciliary&#xD;
             dyskinesia) or accompanied by pulmonary or systemic diseases other than asthma that&#xD;
             lead to increased peripheral blood eosinophil counts (for example, allergic&#xD;
             Bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, eosinophilia&#xD;
             syndrome). COPD with mainly asthma can be included;&#xD;
&#xD;
          -  Asthma subjects:Any disease that has not been stabilized by the investigator,&#xD;
             including but not limited to unstable cardiovascular, gastrointestinal, liver, kidney,&#xD;
             nervous system, musculoskeletal, infectious, endocrine, metabolic, hematology, mental&#xD;
             illness or major physical injury , May: affect the safety of the subject during the&#xD;
             entire study period, affect the research results or interpretation of the results, and&#xD;
             hinder the subject's ability to complete the entire study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaojian Zhang, Bachelor</last_name>
    <phone>+86-0371-66295651</phone>
    <email>Zhxj0524@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Henan</city>
        <state>Zhengzhou</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaojian Zhang, Bachelor</last_name>
      <phone>+86-0371-66295651</phone>
      <email>Zhxj0524@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

